Scinai Seeks €12M Grant to Advance PC111 Through Human Trials

Event summary

  • Scinai submitted a revised €12M application under the FENG SMART Path program to fund PC111 development.
  • The Second Amendment extends PinCell acquisition deadlines to August 31, 2026 (conditions) and September 30, 2026 (exercise).
  • PC111 targets severe autoimmune blistering diseases with no approved therapies for SJS/TEN.
  • Grant would cover 80% of a €15M R&D program, preserving balance sheet flexibility.

The big picture

Scinai's strategic move to secure non-dilutive funding aligns with broader biotech trends of minimizing shareholder dilution while advancing high-risk, high-reward therapies. The focus on severe autoimmune diseases with unmet medical needs positions PC111 for potential accelerated regulatory pathways, a key advantage in the competitive immunotherapy landscape. The €12M grant application represents a critical financing inflection point for the company's development pipeline.

What we're watching

Funding Timing
Whether Scinai receives the €12M grant within the expected 3-4 month window.
Clinical Milestones
The pace at which PC111 advances through non-clinical and First-in-Human datasets.
Regulatory Pathways
How accelerated approval prospects develop for PC111 in severe orphan dermatologic indications.